Objective: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. There are no successful treatments to date. The goal of this research was to determine the efficacy of various doses and the optimal frequency of thymosin β4 (Tβ4) treatment in a murine severe dry eye model.
Research Design And Methods: The study was performed using a controlled adverse environment chamber (CAE) in combination with scopolamine to induce moderate to severe dry eye in mice. The study included five mice per group and tested six different doses of Tβ4 twice per day for 12 days. Tβ4 at 0.1% was also administered 2 - 4 times per day for 12 days. Healing was measured by fluorescein staining.
Main Outcome Measures: Tβ4 significantly reduced the signs of dry eye relative to controls. The treatment effect was more pronounced than the positive controls, doxycycline and Restasis (cyclosporine 0.05%). Active doses of 0.1 and 0.5% were determined, and it was found that the frequency of dosing at 2 times per day was the most effective for healing.
Conclusions: Tβ4 has the potential to be an important new effective therapeutic for dry eye.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14712598.2015.1019858 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Overexpression of tear matrix metalloproteinases-9 (MMP-9) on the ocular surface tissues has been reported to result in ocular surface damage. MMP-9 levels in tears have been listed as one of many tools for confirming dry eye disease (DED).
Objective: This investigation aimed to compare MMP-9 levels and ocular surface parameters in diabetic patients with and without DED.
An update on emerging pharmacological treatments for meibomian gland dysfunction.
Expert Opin Pharmacother
January 2025
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.
View Article and Find Full Text PDFEfficacy and safety of transient receptor potential channel modulators for dry eye: A systematic review and meta-analysis.
Cont Lens Anterior Eye
January 2025
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China; Department of Integrative Medicine, Baoshan Campus of Huashan Hospital, Fudan University, Shanghai, China. Electronic address:
Purpose: To investigate the efficacy and safety of transient receptor potential (TRP) channel modulators for dry eye.
Methods: A thorough search for randomized clinical trials was conducted in seven databases up to February 16, 2024. Suitable studies were identified according to inclusion and exclusion criteria, extracted data were synthesized and analyzed using Review Manager 5.
Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database.
Expert Opin Drug Saf
January 2025
Eye Institute & Affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Background: Dry eye syndrome (DES) significantly affects quality of life. Meibomian Gland Dysfunction (MGD) is a primary contributor to DES and may be drug-induced.
Research Design And Methods: This study analyzed data from the FDA Adverse Event Reporting System (FAERS) between January 2004 and September 2023 using the Ratio of Odds Ratios (ROR) and Proportional Reporting Ratio (PRR) to detect potential drug-induced MGD signals.
Predicting autoimmune thyroiditis in primary Sjogren's syndrome patients using a random forest classifier: a retrospective study.
Arthritis Res Ther
January 2025
Scientific Research Project Department, Guangdong Artificial Intelligence and Digital Economy Laboratory (Guangzhou), Pazhou Lab, Guangzhou, China.
Article Synopsis
- The study examines how effective machine learning, particularly the Random Forest Classifier, is in predicting thyroid-specific autoantibodies in patients with Primary Sjogren's syndrome (pSS) based on clinical data.
- A total of 96 pSS patients were analyzed through thyroid function tests to categorize them by the presence of autoantibodies, leading to the exploration of various risk factors using four different machine learning algorithms.
- The Random Forest Classifier yielded the best results (AUC = 0.755), highlighting age, IgG levels, complement C4, and dry mouth as significant predictors for autoimmune thyroiditis in these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!